ASAIO Journal最新文献

Prosthetic Valve Fate in Patients With Continuous-Flow Left Ventricular Assist Devices. 持续流左心室辅助装置患者的人工瓣膜命运。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-12 DOI: 10.1097/MAT.0000000000002345

Daisuke Kaneyuki, Krushang Patel, Alice V Vinogradsky, Kavya Rajesh, Melissa A Hynds, Paul A Kurlansky, Melana Yuzefpolskaya, Paolo C Colombo, Gabriel T Sayer, Nir Uriel, Yoshifumi Naka, Koji Takeda

{"title":"Prosthetic Valve Fate in Patients With Continuous-Flow Left Ventricular Assist Devices.","authors":"Daisuke Kaneyuki, Krushang Patel, Alice V Vinogradsky, Kavya Rajesh, Melissa A Hynds, Paul A Kurlansky, Melana Yuzefpolskaya, Paolo C Colombo, Gabriel T Sayer, Nir Uriel, Yoshifumi Naka, Koji Takeda","doi":"10.1097/MAT.0000000000002345","DOIUrl":"https://doi.org/10.1097/MAT.0000000000002345","url":null,"abstract":"Prosthetic valve-related morbidity and mortality in patients with left ventricular assist devices (LVADs) remain unclear. We retrospectively reviewed patients who received a HeartMate II or 3 LVAD at our center between April 2004 and December 2022. Patients with a valve prosthesis in any position were included. Of the 726 LVAD recipients, 74 (10.2%) underwent valve replacement before (n = 37, 50.0%), concomitantly with (n = 32, 43.2%), or after (n = 6, 8.1%) LVAD insertion. Prosthetic valves were implanted in the aortic (n = 32), mitral (n = 23), and tricuspid (n = 26) positions. Mechanical valves were present in eight (three aortic, five mitral) patients. At a median follow-up of 1.97 years post-VAD (interquartile range [IQR]: 0.56-4.58 years), there was one valve-related death due to severe aortic bioprosthetic insufficiency. Five of 28 (17.9%) patients with an aortic bioprosthesis had evidence of dysfunction on follow-up echocardiography. Median time to first sign of aortic bioprosthetic valve dysfunction was 1 (IQR: 0.6-5.1) year from time of LVAD with the prosthesis in place and 10.8 (IQR: 9.5-12.6) years from date of initial valve insertion. Prosthetic valve-related mortality or reinterventions are uncommon in patients with LVADs; however, bioprosthetic aortic valve dysfunction can develop less than 1 year after LVAD implantation.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Transplantation Outcomes in Patients With Hypertrophic Cardiomyopathy in the Era of Mechanical Circulatory Support. 机械循环支持时代肥厚型心肌病患者的心脏移植结果。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-11 DOI: 10.1097/MAT.0000000000002347

Matylda Mazur, Robert Dowling, Geetha Bhat, Andres Carmona Rubio, Howard J Eisen

{"title":"Heart Transplantation Outcomes in Patients With Hypertrophic Cardiomyopathy in the Era of Mechanical Circulatory Support.","authors":"Matylda Mazur, Robert Dowling, Geetha Bhat, Andres Carmona Rubio, Howard J Eisen","doi":"10.1097/MAT.0000000000002347","DOIUrl":"https://doi.org/10.1097/MAT.0000000000002347","url":null,"abstract":"Mechanical circulatory support has emerged as a vital therapeutic modality for patients awaiting heart transplantation (HT). However, it is unknown how it affected the characteristics and post-HT outcomes of patients with hypertrophic cardiomyopathy (HCM). This retrospective cohort study analyzed adult HT recipients from the International Society for Heart and Lung Transplantation registry (1998-2017). Two equal-duration eras were defined: era 1 1998-2007 and era 2 2008-2017. Patients with HCM were compared across the two eras (n1 = 742 and n2 = 1,211) and within each era, they were contrasted with individuals with nonischemic (NICM) (n1 = 15,964 and n2 = 20,394) and ischemic cardiomyopathy (ICM) (n1 = 14,140 and n2 = 12,986). Across eras, the number of HTs among patients with HCM increased by 63%. The rate of recipients with HCM in the intensive care unit (ICU) supported with intra-aortic balloon pump (IABP) increased, yet their pre-HT functional status improved, and 5 year post-HT survival remained unchanged and favorable. In era 2, at the time of HT, patients with HCM were more frequently than their NICM and ICM counterparts in the ICU and supported with inotropes. In the same era, 1 and 5 year survival were more favorable in HCM compared to ICM and comparable to NICM.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply Letter to Editor to Daniel Schneditz. 给编辑丹尼尔-施内迪茨的回信。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-06 DOI: 10.1097/MAT.0000000000002336

Dilek Karacanoğlu, Benan Bayrakci

引用次数: 0

Predictive Accuracy of HeartMate 3 Risk Score After the Heart Transplant Allocation Change. 心脏移植分配变化后 HeartMate 3 风险评分的预测准确性。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-06 DOI: 10.1097/MAT.0000000000002343

Justin D Vincent, Alyssa Ramsay, David S Lambert, Elena Deych, Ana María Pico, Erin Coglianese, Justin M Vader, Bin Q Yang

引用次数: 0

Three-Dimensional Bio-Printed Tubular Tissue Using Dermal Fibroblast Cells as a New Tissue-Engineered Vascular Graft for Venous Replacement. 利用真皮成纤维细胞的三维生物打印管状组织作为用于静脉置换的新型组织工程血管移植物

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-01 Epub Date: 2024-05-03 DOI: 10.1097/MAT.0000000000002224

Makoto Hayasaka, Takashi Kokudo, Junichi Kaneko, Takehiro Chiyoda, Anna Nakamura, Manabu Itoh, Kazuhiro Endo, Koichi Nakayama, Kiyoshi Hasegawa

{"title":"Three-Dimensional Bio-Printed Tubular Tissue Using Dermal Fibroblast Cells as a New Tissue-Engineered Vascular Graft for Venous Replacement.","authors":"Makoto Hayasaka, Takashi Kokudo, Junichi Kaneko, Takehiro Chiyoda, Anna Nakamura, Manabu Itoh, Kazuhiro Endo, Koichi Nakayama, Kiyoshi Hasegawa","doi":"10.1097/MAT.0000000000002224","DOIUrl":"10.1097/MAT.0000000000002224","url":null,"abstract":"The current study was a preliminary evaluation of the feasibility and biologic features of three-dimensionally bio-printed tissue-engineered (3D bio-printed) vascular grafts comprising dermal fibroblast spheroids for venous replacement in rats and swine. The scaffold-free tubular tissue was made by the 3D bio-printer with normal human dermal fibroblasts. The tubular tissues were implanted into the infrarenal inferior vena cava of 4 male F344-rnu/rnu athymic nude rats and the short-term patency and histologic features were analyzed. A larger 3D bio-printed swine dermal fibroblast-derived prototype of tubular tissue was implanted into the right jugular vein of a swine and patency was evaluated at 4 weeks. The short-term patency rate was 100%. Immunohistochemistry analysis showed von Willebrand factor positivity on day 2, with more limited positivity observed on the luminal surface on day 5. Although the cross-sectional area of the wall differed significantly between preimplantation and days 2 and 5, suggesting swelling of the tubular tissue wall (both p < 0.01), the luminal diameter of the tubular tissues was not significantly altered during this period. The 3D bio-printed scaffold-free tubular tissues using human dermal or swine fibroblast spheroids may produce better tissue-engineered vascular grafts for venous replacement in rats or swine.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"1008-1014"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Right Ventricular Dysfunction in Pediatric Acute Respiratory Distress Syndrome on Venovenous Extracorporeal Membrane Oxygenation. 静脉体外膜氧合治疗小儿急性呼吸窘迫综合征的新右心室功能障碍。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-01 Epub Date: 2024-06-19 DOI: 10.1097/MAT.0000000000002257

Caroline Holton, Sanket Shah, Jenna O Miller

{"title":"New Right Ventricular Dysfunction in Pediatric Acute Respiratory Distress Syndrome on Venovenous Extracorporeal Membrane Oxygenation.","authors":"Caroline Holton, Sanket Shah, Jenna O Miller","doi":"10.1097/MAT.0000000000002257","DOIUrl":"10.1097/MAT.0000000000002257","url":null,"abstract":"The development of new right ventricular (RV) dysfunction after cannulation to venovenous (VV) extracorporeal membrane oxygenation (ECMO) and its association with worse outcomes is increasingly recognized in adult patients, however, no studies have evaluated this phenomenon in pediatric patients. We report results of a single-center retrospective cohort study at a large academic children's hospital. New RV systolic dysfunction was present in 48% (12/25) of pediatric patients on VV ECMO for acute respiratory distress syndrome (ARDS). There was no statistically significant difference in survival, duration of mechanical ventilation, or hospital length of stay between those with and without RV dysfunction. Over half (5/9, 56%) of survivors with RV dysfunction on ECMO had RV dilation or RV hypertrophy on post-ECMO echocardiograms, and in two patients the RV dysfunction persisted for months following decannulation. Cardiac catheterization and autopsy reports suggested that echocardiographic assessment of RV systolic function alone may not be sufficient to diagnose clinically relevant RV injury. This is the first study to report the prevalence of RV dysfunction on VV ECMO for pediatric ARDS. Future multicenter collaboration is needed to create a clinically relevant definition of pediatric \"RV injury\" and to further evaluate risk factors and outcomes of RV dysfunction.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"994-1000"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Volume Displacement Pulsatile Veno-Arterial Extracorporeal Membrane Oxygenation: Preliminary Data From In Vitro Tests. 体积置换脉动性静脉-动脉体外膜氧合：体外试验的初步数据。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-01 Epub Date: 2024-03-29 DOI: 10.1097/MAT.0000000000002207

Silver Heinsar, Clayton Semenzin, Samia M Farah, John F Fraser

引用次数: 0

Meet the Authors. 与作者见面

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-01 Epub Date: 2024-10-25 DOI: 10.1097/01.mat.0001081416.36880.1e

引用次数: 0

ECMO Alone Versus ECPELLA in Patients Affected by Cardiogenic Shock: The Multicenter EVACS Study. 心源性休克患者单用 ECMO 与 ECPELLA 的对比：多中心 EVACS 研究。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-01 Epub Date: 2024-05-03 DOI: 10.1097/MAT.0000000000002219

Antonio Piperata, Jef Van den Eynde, Charles-Henri David, Ahmet Ruchan Akar, Masazumi Watanabe, Ilias Doulamis, Pierre-Guillaume Piriou, Mehmet Cahit Saricaoğlu, Hiroki Ikenaga, Thomas Gouttenegre, Mickael Vourc'h, Shinya Takahashi, Alexandre Ouattara, Louis Labrousse, Giacomo Frati, Mathieu Pernot

{"title":"ECMO Alone Versus ECPELLA in Patients Affected by Cardiogenic Shock: The Multicenter EVACS Study.","authors":"Antonio Piperata, Jef Van den Eynde, Charles-Henri David, Ahmet Ruchan Akar, Masazumi Watanabe, Ilias Doulamis, Pierre-Guillaume Piriou, Mehmet Cahit Saricaoğlu, Hiroki Ikenaga, Thomas Gouttenegre, Mickael Vourc'h, Shinya Takahashi, Alexandre Ouattara, Louis Labrousse, Giacomo Frati, Mathieu Pernot","doi":"10.1097/MAT.0000000000002219","DOIUrl":"10.1097/MAT.0000000000002219","url":null,"abstract":"The objective was to investigate the outcomes of concomitant venoarterial extracorporeal membrane oxygenation (ECMO) and left ventricular unloading with Impella (ECPELLA) compared with ECMO alone to treat patients affected by cardiogenic shock. Data from patients needing mechanical circulatory support from 4 international centers were analyzed. Of 438 patients included, ECMO alone and ECPELLA were adopted in 319 (72.8%) and 119 (27.2%) patients, respectively. Propensity score matching analysis identified 95 pairs. In the matched cohort, 30-day mortality rates in the ECMO and ECPELLA were 49.5% and 43.2% ( P = 0.467). The incidences of complications did not differ significantly between groups ( P = 0.877, P = 0.629, P = 1.000, respectively). After a median follow-up of 0.18 years (interquartile range 0.02-2.55), the use of ECPELLA was associated with similar mortality compared with ECMO alone (hazard ratio 0.81, 95% confidence interval 0.54-1.20, P = 0.285), with 1-year overall survival rates of 51.3% and 46.6%, for ECPELLA and ECMO alone, respectively. ECMO alone and ECPELLA are both effective strategies in patients needing mechanical circulatory support for cardiogenic shock, showing similar rates of early and mid-term survival.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"946-953"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in Donor Utilization and Outcomes for Patients Bridged With Durable Left Ventricular Assist Device. 使用耐用左心室辅助装置进行桥接的患者使用捐赠者和治疗效果的变化。

IF 3.1 3区医学

ASAIO Journal Pub Date : 2024-11-01 Epub Date: 2024-05-10 DOI: 10.1097/MAT.0000000000002228

Armaan F Akbar, Dianela Perdomo, Benjamin L Shou, Alice L Zhou, Jessica M Ruck, Ahmet Kilic

{"title":"Changes in Donor Utilization and Outcomes for Patients Bridged With Durable Left Ventricular Assist Device.","authors":"Armaan F Akbar, Dianela Perdomo, Benjamin L Shou, Alice L Zhou, Jessica M Ruck, Ahmet Kilic","doi":"10.1097/MAT.0000000000002228","DOIUrl":"10.1097/MAT.0000000000002228","url":null,"abstract":"We studied the impact of the 2018 heart allocation policy change on donor characteristics and posttransplant outcomes of left ventricular assist device (LVAD)-bridged heart transplant (HT) recipients. Left ventricular assist device-bridged adult HT recipients from October 2014 to October 2022 in the United Network for Organ Sharing database were categorized into old allocation policy (OAP) and new allocation policy (NAP) cohorts. Baseline characteristics, posttransplant outcomes, and subgroup analyses of unstable and stable LVAD-bridged recipients were assessed. The study included 7,384 HT recipients; 4,345 (58.8%) were transplanted in the OAP era and 3,039 (41.2%) in the NAP era. Old allocation policy recipients were most frequently status 1A at transplantation (71.1%), whereas NAP recipients were most frequently status 3 (40.0%), and status 4 (31.9%). Median donor sequence number (DSN) was higher in the NAP versus OAP era (9 vs. 3, p < 0.001). On multivariable analysis, NAP recipients had 20% higher 1 year mortality compared to OAP (adjusted hazard ratio [aHR] = 1.20 [95% confidence interval {CI}: 1.04-1.40], p = 0.01). Status 1 or 2 recipients had 28% higher 1 year mortality compared to status 1A (aHR = 1.28 [95% CI: 1.01-1.63], p = 0.04). Status 1 and 2 LVAD-supported recipients had higher mortality following the 2018 allocation change, indicating the need for closer surveillance of LVAD-bridged patients who may decompensate on the waitlist.","PeriodicalId":8844,"journal":{"name":"ASAIO Journal","volume":" ","pages":"964-970"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140903443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0